Prevention and control of influenza with vaccines: Recommendations of the advisory committee on immunization practices, United States, 2015–16 influenza season

Morbidity and Mortality Weekly Report

Volumn 64, Issue 30, 2015, Pages 818-825

  Grohskopf, Lisa A ^a   Sokolow, Leslie Z ^a,b   Olsen, Sonja J ^a   Bresee, Joseph S ^a   Broder, Karen R ^c   Karron, Ruth A ^d  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b BATTELLE MEMORIAL INSTITUTE   (United States)

^c NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE;

ADVISORY COMMITTEE; CHILD; HUMAN; IMMUNIZATION; IMMUNOLOGY; INFANT; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); INFLUENZA B VIRUS; INFLUENZA, HUMAN; PRESCHOOL CHILD; SEASON; UNITED STATES;

ADVISORY COMMITTEES; CHILD; CHILD, PRESCHOOL; HUMANS; IMMUNIZATION SCHEDULE; INFANT; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; SEASONS; UNITED STATES; VACCINES, ATTENUATED; VACCINES, INACTIVATED;

EID: 84939184101     PISSN: 01492195     EISSN: 1545861X     Source Type: Journal    
DOI: 10.15585/mmwr.mm6430a3     Document Type: Article

References (40)

1. Grohskopf LA, Olsen SJ, Sokolow LZ, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP) — United States, 2014–15 influenza season. MMWR Morb Mortal Wkly Rep 2014;63:691–7.
2. CDC. Prevention and control of seasonal influenza with vaccines. recommendations of the Advisory Committee on Immunization Practices— United States, 2013–14. MMWR Recomm Rep 2013;62(No. RR-7):1–43.
3. Ochiai H, Shibata M, Kamimura K, Niwayama S. Evaluation of the efficacy of split-product trivalent A(H1N1), A(H3N2), and B influenza vaccines: reactogenicity, immunogenicity and persistence of antibodies following two doses of vaccines. Microbiol Immunol 1986;30:1141–9.
4. Künzel W, Glathe H, Engelmann H, Van Hoecke C. Kinetics of humoral antibody response to trivalent inactivated split influenza vaccine in subjects previously vaccinated or vaccinated for the first time. Vaccine 1996;14:1108–10.
5. Song JY, Cheong HJ, Hwang IS, et al. Long-term immunogenicity of influenza vaccine among the elderly: Risk factors for poor immune response and persistence. Vaccine 2010;28:3929–35.
6. Skowronski DM, Tweed SA, De Serres G. Rapid decline of influenza vaccine-induced antibody in the elderly: is it real, or is it relevant? J Infect Dis 2008;197:490–502.
7. Castilla J, Martínez-Baz I, Martínez-Artola V, et al. Network for Influenza Surveillance in Hospitals of Navarre. Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011/12. Euro Surveill 2013;18:20388.
8. Food and Drug Administration. 138th Meeting of the Vaccines and Related Biological Produces Advisory Committee, March 4, 2015 [Transcript]. Washington, DC: Food and Drug Administration; 2015. Available at http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/ VaccinesandRelatedBiologicalProductsAdvisoryCommittee/UCM438843.pdf.
9. bioCSL. Afluria: Influenza Vaccine [Package insert]. King of Prussia, PA: bioCSL; 2015. Available at http://www.fda.gov/downloads/ BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM263239.pdf.
10. McAllister L, Anderson J, Werth K, et al. Needle-free jet injection for administration of influenza vaccine: a randomised non-inferiority trial. Lancet 2014;384:674–81.
11. Protein Sciences. Flublok: Influenza Vaccine [Package insert]. Meriden, CT: Protein Sciences; 2015. Available at http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM336020.pdf.
12. Keitel WA, Treanor JJ, El Sahly HM, et al. Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccine (TIV) among persons ≥65 years old. Vaccine 2009;28:379–85.
13. Baxter R, Patriarca PA, Ensor K, Izikson R, Goldenthal KL, Cox MM. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50–64 years of age. Vaccine 2011;29:2272–8.
14. National Institutes of Health. Comparison of the safety of Flublok® versus licensed IIV in healthy, medically stable adults ≥50 years of age [Internet]. Bethesda, MD: National Institutes of Health; 2015. Clinical study record no. NC0125200. Available from: https://clinicaltrials.gov/ct2/show/NCT01825200.
15. Sanofi Pasteur. Fluzone Intradermal Quadrivalent vaccine [Package insert]. Swiftwater, PA: Sanofi Pasteur; 2015. Available at http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM426679.pdf.
16. Gorse GJ, Falsey AR, Ozol-Godfrey A, Landolfi V, Tsang PH. Safety and immunogenicity of a quadrivalent intradermal influenza vaccine in adults. Vaccine 2015;33:1151–9.
17. Neuzil KM, Jackson LA, Nelson J, et al. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5–8-year-old children. J Infect Dis 2006;194:1032–9.
18. Allison MA, Daley MF, Crane LA, et al. Influenza vaccine effectiveness in healthy 6- to 21-month-old children during the 2003-2004 season. J Pediatr 2006;149:755–62.
19. Ritzwoller DP, Bridges CB, Shetterly S, Yamasaki K, Kolczak M, France EK. Effectiveness of the 2003–2004 influenza vaccine among children 6 months to 8 years of age, with 1 vs 2 doses. Pediatrics 2005;116:153–9.
20. Englund JA, Walter EB, Gbadebo A, Monto AS, Zhu Y, Neuzil KM. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers. Pediatrics 2006;118:e579–85.
21. Englund JA, Walter EB, Fairchok MP, Monto AS, Neuzil KM. A comparison of 2 influenza vaccine schedules in 6- to 23-month-old children. Pediatrics 2005;115:1039–47.
22. Walter EB, Neuzil KM, Zhu Y, et al. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming? Pediatrics 2006;118:e570–8.
23. Ambrose CS, Levin MJ, Belshe RB. The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults. Influenza Other Respir Viruses 2011;5:67–75.
24. Belshe RB, Edwards KM, Vesikari T, et al.; CAIV-T Comparative Efficacy Study Group. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007;356:685–96.
25. Ashkenazi S, Vertruyen A, Arístegui J, et al.; CAIV-T Study Group. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 2006;25:870–9.
26. Fleming DM, Crovari P, Wahn U, et al.; CAIV-T Asthma Study Group. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 2006;25:860–9.
27. Advisory Committee on Immunization Practices (ACIP). Summary Report: October 29–30, 2014 (Meeting minutes). Washington, DC: US Department of Health and Human Services, CDC; 2014. Available at http://www.cdc.gov/vaccines/acip/meetings/downloads/min-archive/ min-2014-10.pdf.
28. Advisory Committee on Immunization Practices (ACIP). Summary Report: February 26, 2015 (Meeting minutes). Washington, DC: US Department of Health and Human Services, CDC; 2015. Available at http://www.cdc.gov/vaccines/acip/meetings/downloads/min-archive/min-2015-02.pdf.
29. Medimmune. Flumist Quadrivalent [Draft of package insert]. Gaithersburg, MD: MedImmune; 2015 Available at http://www.fda.gov/downloads/ BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM294307.pdf.
30. Des Roches A, Paradis L, Gagnon R, Lemire C, Begin P, Carr S, et al. Egg-allergic patients can be safely vaccinated against influenza. J Allergy Clinical Immunol 2012;130:1213–6 e1.
31. Kelso JM, Greenhawt MJ, Li JT; Joint Task Force on Practice Parameters (JTFPP). Update on influenza vaccination of egg allergic patients. Ann Allergy Asthma Immunol 2013;111:301–2.
32. Advisory Committee on Immunization Practices (ACIP). Summary Report: June 20–21, 2012 (Meeting minutes). Washington, DC: US Department of Health and Human Services, CDC; 2012. Available at http://www.cdc.gov/vaccines/acip/meetings/downloads/min-archive/min-jun12.pdf.
33. Advisory Committee on Immunization Practices (ACIP). Summary Report: June 19–20, 2013 (Meeting minutes). Washington, DC: US Department of Health and Human Services, CDC; 2013. Available at http://www.cdc.gov/vaccines/acip/meetings/downloads/min-archive/min-jun13.pdf.
34. Kelso JM, Greenhawt MJ, Li JT, et al. Adverse reactions to vaccines practice parameter 2012 update. J Allergy Clin Immunol 2012;130:25–43.
35. Owens G, MacGinnitie A. Higher-ovalbumin-content influenza vaccines are well tolerated in children with egg allergy. J Allergy Clin Immunol 2011;127:264–5.
36. Des Roches A, Samaan K, Graham F, et al. Safe vaccination of patients with egg allergy by using live attenuated influenza vaccine. J Allergy Clin Immunol Pract 2015;3:138–9.
37. Turner PJ, Southern J, Andrews NJ, Miller E, Erlewyn-Lajeunesse M, SNIFFLE Study Investigators. Safety of live attenuated influenza vaccine in atopic children with egg allergy. J Allergy Clinical Immunol 2015; pii: S0091–6749(15)00005–6.
38. CDC. General recommendations on immunization—recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011;60(No. RR-2):1–64.
39. Erlewyn-Lajeunesse M, Brathwaite N, Lucas JS, Warner JO. Recommendations for the administration of influenza vaccine in children allergic to egg. BMJ 2009;339:b3680.
40. Rubin LG, Levin MJ, Ljungman P, et al.; Infectious Diseases Society of America. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014;58:e44–100.